GLP-1 receptor agonists have quietly displaced metformin at the top of the type 2 diabetes treatment hierarchy. Here's the clinical evidence behind that shift — and what it means for patients who can't afford brand-name options.
Quick Summary: The American Diabetes Association's 2025 Standards of Care elevated GLP-1 receptor agonists and SGLT2 inhibitors to preferred agents for type 2 diabetes management — ahead of metformin — for most patients with established cardiovascular disease, chronic kidney disease, or high cardiovascular risk. The clinical evidence driving this change is overwhelming: A1c reductions of 1.5–2.5%, 24% reduction in kidney disease progression (FLOW trial), and 20-26% reduction in major cardiovascular events (SELECT, LEADER trials). For T2D patients priced out of brand-name options, compounded semaglutide is now the primary access pathway.
For nearly 60 years, metformin was the unquestioned first-line medication for type 2 diabetes. Inexpensive, well-tolerated, and modestly effective, it became the default starting point for essentially every newly diagnosed T2D patient worldwide. That consensus has now fractured — not because metformin got worse, but because GLP-1 receptor agonists got dramatically better.
The 2025 American Diabetes Association (ADA) Standards of Care, updated in January 2025, reflect a clinical evidence base that now clearly favors GLP-1 receptor agonists as the preferred initial pharmacotherapy for most people with T2D who also have established cardiovascular disease, chronic kidney disease, or high cardiovascular risk — which describes the majority of T2D patients seeking treatment in March 2026.
This isn't a subtle preference shift. The ADA's position reflects three converging streams of clinical trial evidence: A1c reduction superiority, cardiovascular outcome benefits, and kidney protection data that earlier diabetes drugs simply never demonstrated. Each of these independently would be notable; together, they represent a category-defining advantage.
The core job of any diabetes drug is glucose control — and GLP-1 receptor agonists deliver. Published data from major clinical programs shows:
To put these numbers in context: achieving a 1% A1c reduction is associated with a 14% reduction in myocardial infarction risk and 37% reduction in microvascular complications in observational data. A 2% reduction, achievable with tirzepatide in many patients, represents transformative risk reduction for the long-term complications of T2D.
The FLOW trial — the first dedicated kidney outcome trial for any GLP-1 receptor agonist — published its primary results in 2024, and the data genuinely surprised the nephrology community. Semaglutide 1mg significantly reduced the composite of kidney failure, substantial reduction in kidney function, or kidney or cardiovascular death in patients with T2D and chronic kidney disease.
The primary endpoint was reduced by approximately 24% — a clinically significant benefit in a population with notoriously limited treatment options. Semaglutide also reduced cardiovascular death and all-cause mortality as secondary endpoints in this CKD population. Based on these results, the FDA approved semaglutide for the reduction of kidney disease progression and cardiovascular risk in adults with T2D and CKD.
Why were nephrologists surprised? Previous kidney-protective diabetes drugs — particularly SGLT2 inhibitors — had established a benchmark that was widely considered close to the ceiling of achievable kidney protection in T2D. FLOW showed that GLP-1 receptor agonists can achieve comparable or additive kidney protection through distinct mechanisms, opening the door to combination approaches and broadening the therapeutic toolkit for CKD patients significantly.
The cardiovascular outcome data for GLP-1 receptor agonists is now a decade deep, spanning multiple drugs and populations:
The LEADER trial (liraglutide) established the cardiovascular benefit class effect in 2016, showing a 13% reduction in major adverse cardiovascular events (MACE) versus placebo in high-risk T2D patients. The SUSTAIN-6 trial (semaglutide) extended this with a 26% MACE reduction. These results drove initial guideline changes.
The SELECT trial — completed in 2023 and published in the New England Journal of Medicine — took a critical additional step: it enrolled patients with obesity and established cardiovascular disease who did not have diabetes. The 20% MACE reduction in this non-diabetic population proved that GLP-1's cardiovascular benefit operates independently of its diabetes mechanism. It is not just about better glucose control — there is a distinct cardiometabolic effect on vascular biology, inflammation, and cardiac function.
For T2D patients who also have established CVD — roughly 30–40% of the T2D population — GLP-1 receptor agonists are now the only weight-loss medication class with an FDA-approved cardiovascular mortality reduction indication. That's not a marketing claim; it's a regulatory determination based on randomized trial evidence.
Compounded semaglutide delivers the same active molecule as Ozempic — through licensed telehealth programs, starting at $150–$300/month.
Here is the access problem in plain terms: Ozempic (semaglutide for diabetes) lists at approximately $900–$970 per month without insurance. Most commercially insured T2D patients have coverage — but Medicare Part D, Medicaid, and uninsured patients face very different realities, and even insured patients face tier 3 cost-sharing that can run $100–$300+ per month out of pocket.
Compounded semaglutide — legally prepared by licensed 503A and 503B compounding pharmacies using pharmaceutical-grade API — provides the same active molecule at dramatically lower cost. Programs like Synergy Rx, MEDVi, and Care Bare Rx provide compounded semaglutide including telehealth consultation for $150–$350/month all-in.
It is critical to understand what "compounded" means in this context: it means a licensed pharmacy has prepared a semaglutide formulation from qualified API sources, under a valid prescription from a licensed provider. The medication is not FDA-approved in the same sense as Ozempic — it has not gone through Novo Nordisk's manufacturing quality program or clinical trial program — but the active molecule is the same and the legal framework for compounding is well-established under federal law.
For T2D patients whose clinical picture indicates they need GLP-1 therapy but who cannot afford brand-name options, this is a legitimate and important access pathway. See our guide to the legal status of compounded semaglutide for the full regulatory framework.
Both are excellent choices for T2D. The key clinical differences that should guide the decision:
For a comprehensive comparison, see our definitive semaglutide vs. tirzepatide head-to-head.
One of the most important emerging practice patterns in T2D management is combining GLP-1 receptor agonists with SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin). These two drug classes work through completely different mechanisms — GLP-1 acts primarily centrally and on the pancreas; SGLT2 inhibitors act on the kidney to increase glucose excretion — and their benefits appear largely additive.
The combination provides: complementary A1c reduction, combined cardiovascular protection (both classes have independent CV benefits), kidney protection from two distinct mechanisms, and weight loss from both pathways. For T2D patients with both CVD and CKD — a very common profile — guidelines now support this combination as the preferred approach when tolerated.
If you're currently on an SGLT2 inhibitor and your T2D is not at goal, or if you have both CKD and CVD, ask your provider specifically about adding a GLP-1 receptor agonist. The combination may be the most clinically appropriate option available.
Care Bare Rx offers physician-supervised programs with clinical expertise in metabolic conditions including type 2 diabetes.
Get Started with Care Bare Rx →All clinical claims sourced from peer-reviewed literature, ADA Standards of Care, FDA documents, and named clinical trials. No Fluff. Just Sources.
T2D-experienced telehealth programs